Pfizer, a giant U.S. drug manufacturer along with the Germany’s BioNTech, is a frontrunner in the global race to develop a safe and effective Covid-19 vaccine. While the vaccine has not gotten the approval, it has started manufacturing the thousands of vaccines ahead of the anticipated vaccine approval time in November. Company’s factory is situated in Puurs, Belgium, where vaccine is being manufactured which is now stockpiled and ready to deliver worldwide.
Should vaccine get approval, the company claims to manufacture over 100 million doses this year, with more plans to mass produce over 1.3 billion in 2021. Furthermore, it is claimed that out of 100 million doses, 40 million are destined to dispatch to the UK. Furthermore, it is revealed that each patient will need up to two vaccine doses.
Moreover, the company’s CEO released a public statement last week, clarifying its best estimates for when they could apply for emergency approval. The best estimated time by Pfizer’s, third week of November will be the earliest they will be able to apply for approval.
Transparency is important so I’d like to provide greater clarity around the timelines for @pfizer’s #COVID19 vaccine and the 3 key areas where we must demonstrate success in order to submit for Emergency Use Authorization (EUA) or Approval: https://t.co/EVSnMNoeRQ
— AlbertBourla (@AlbertBourla) October 16, 2020
Will Kids Get A COVID-19 Vaccine? Pfizer To Expand Trial To Ages 12 And Up https://t.co/ohEsZAVWUm
— NPR Health News (@NPRHealth) October 13, 2020
Alongside, the UK’s deputy chief medical officer, Jonathan Van-Tam, stated that the stage three trials of the vaccine created at Oxford University mass produced by Astra Zeneca, could be rolled-out in December.
According to him, “’We aren’t light years away from it. It isn’t a totally unrealistic suggestion that we could deploy a vaccine soon after Christmas.”
As per WHO data, more than 27 potential Covid-19 vaccines have been tested globally, while over 139 vaccines are in the development phase pre-trial. Since the outbreak, China has been on a roller coaster to speed up the vaccine development. Chinese drug companies have developed vaccines, from which 5 vaccines are in final stages of testing, but none is approved for public use.
While the vaccines have not been granted approval, ore than 350,000 people outside its clinical trials have got the vaccines, a company executive said in September. Additionally, China is in talks to have its locally produced Covid-19 vaccines assessed by the World Health Organization, which is believed a step forward towards making them available for international use.
Socorro Escalate, WHO’s coordinator for essential medicines and health technologies in the Western Pacific region, told a news conference conducted online, “China had held preliminary discussions with WHO to have its vaccines included in a list for emergency use. “
Meanwhile, in India, the second most worst effected country by Covid-19 after US, the India-based Zydus Cadila has launched Phase II clinical trials of locally produced ZyCoV-D vaccine previously, which was found to be safe and effective in healthy participants. In the second phase, it was planned to test the vaccine in more than 1,000 healthy adults.
Lastly, awhile preparing for the vaccine deployment, it is stated that thousands of NHS staff are to undergo training to administer a vaccine before the end of the year.